|
children |
25 |
|
covid-19 |
16 |
|
sars-cov-2 |
13 |
|
adolescents |
12 |
|
convalescence |
12 |
|
sars-cov-2 rbd igg |
12 |
|
t cell response |
12 |
|
immunotherapy |
11 |
|
vaccine |
11 |
|
allergy |
10 |
|
asparaginase |
10 |
|
chinese |
10 |
|
human leukocyte antigens |
10 |
|
hypersensitivity |
10 |
|
antimicrobial resistance |
8 |
|
bacteria |
8 |
|
infants |
8 |
|
meningitis |
8 |
|
neonates |
8 |
|
adolescent |
7 |
|
coronavac |
7 |
|
omicron |
7 |
|
extracellular vesicle |
6 |
|
head and neck neoplasms |
6 |
|
radiotherapy |
6 |
|
t-lymphocytes |
6 |
|
tumor |
6 |
|
tumor microenvironment |
6 |
|
γδ t cells |
6 |
|
γδ-t cells |
6 |
|
ampk |
5 |
|
glucose metabolism |
5 |
|
lactate |
5 |
|
t2dm |
5 |
|
tumor surveillance |
5 |
|
pediatrics |
4 |
|
allogeneic transplantation |
3 |
|
bone marrow transplantation |
3 |
|
hematopoietic stem cell transplantation |
3 |
|
immune reconstitution |
3 |
|
infections |
3 |
|
acute lymphoblastic leukemia |
2 |
|
acute myeloid leukemia |
2 |
|
adenovirus |
2 |
|
allogeneic bmt |
2 |
|
allogeneic bone marrow transplantation |
2 |
|
aml |
2 |
|
aplastic anemia |
2 |
|
autologous transplantation |
2 |
|
bone marrow transplant |
2 |
|
cancer |
2 |
|
cd34 selection |
2 |
|
child |
2 |
|
childhood |
2 |
|
childhood leukemia |
2 |
|
graft-versus-host disease |
2 |
|
haploidentical |
2 |
|
hematopoietic stem cell |
2 |
|
hemorrhagic cystitis |
2 |
|
high-dose chemotherapy |
2 |
|
langerhans cell histiocytosis |
2 |
|
leukemia |
2 |
|
myelodysplastic syndrome |
2 |
|
natural killer cells |
2 |
|
neuroblastoma |
2 |
|
oncology |
2 |
|
paediatric |
2 |
|
pediatric |
2 |
|
relapse |
2 |
|
second malignancy |
2 |
|
stem cell transplantation |
2 |
|
survival |
2 |
|
transplantation |
2 |
|
abdominal |
1 |
|
acute gvhd |
1 |
|
acute lymphoblastic leukaemia |
1 |
|
acute myeloid leukaemia |
1 |
|
adoptive cell therapy |
1 |
|
adoptive immunotherapy |
1 |
|
alloegenic hematopoietic cell transplantation |
1 |
|
allogeneic |
1 |
|
allogeneic hematopoietic stem cell transplantation |
1 |
|
allogeneic hsct |
1 |
|
allogeneic stem cell transplantation |
1 |
|
antithymocyte globulin |
1 |
|
aplastic anemia engraftment |
1 |
|
asymptomatic |
1 |
|
atmp |
1 |
|
atovaquone |
1 |
|
autogvhd |
1 |
|
autologous |
1 |
|
autologous bmt |
1 |
|
autologous hsct |
1 |
|
b cells |
1 |
|
baboon envelope |
1 |
|
biological assay |
1 |
|
biological assays |
1 |
|
bk virus |
1 |
|
bmt immunology |
1 |
|
bone marrow metastasis |
1 |
|
brain necrosis |
1 |
|
bronchoalveolar lavage |
1 |
|
bronchoscopy |
1 |
|
car |
1 |
|
caregiver preferences |
1 |
|
cd34 |
1 |
|
cd34 cells + |
1 |
|
cd34 progenitors |
1 |
|
cd45ra depletion |
1 |
|
cd5 b cells + |
1 |
|
cell therapy |
1 |
|
cellular therapy |
1 |
|
cendritic cell |
1 |
|
childhood acute lymphoblastic leukemia |
1 |
|
childhood aml |
1 |
|
chimera assays |
1 |
|
cidofovir |
1 |
|
circulating tumor cells |
1 |
|
clearance |
1 |
|
clinical nk cell studies |
1 |
|
clinical trial |
1 |
|
clinimacs |
1 |
|
clofarabine |
1 |
|
competing risk |
1 |
|
complications |
1 |
|
computed tomography |
1 |
|
computed tomography (ct) |
1 |
|
conditioning regimen |
1 |
|
conditioning regimen intensity |
1 |
|
cord blood |
1 |
|
cx3cr1 |
1 |
|
cy |
1 |
|
cyclooxygenase-2 |
1 |
|
cytogenetics |
1 |
|
cytotoxicity |
1 |
|
defibrotide |
1 |
|
dli |
1 |
|
dna damage |
1 |
|
dyskeratosis congenita |
1 |
|
ebv |
1 |
|
encephalopathy |
1 |
|
engraftment |
1 |
|
engraftment syndrome |
1 |
|
enteral nutrition |
1 |
|
epstein-barr virus |
1 |
|
etv6-runx1 |
1 |
|
ewing sarcoma |
1 |
|
ewing's sarcoma |
1 |
|
ex vivo expansion |
1 |
|
exvivo expansion |
1 |
|
gd2 monoclonal antibody |
1 |
|
genetic association study |
1 |
|
good manufacturing practice (gmp) |
1 |
|
graft failure |
1 |
|
graft versus host disease |
1 |
|
graft-versus-host disease (gvhd) |
1 |
|
graft-versus-tumor |
1 |
|
graft-versus-tumor effect |
1 |
|
graft-vs-host disease |
1 |
|
gvhd |
1 |
|
haematological malignancy |
1 |
|
haematopoietic stem cell transplantation |
1 |
|
haploidentical donor |
1 |
|
haploidentical donors |
1 |
|
haploidentical haematopoietic stem cell transplantation |
1 |
|
haploidentical stem cell transplantation |
1 |
|
haploidentical transplantation |
1 |
|
healthcare providers preferences |
1 |
|
hematopoiesis |
1 |
|
hematopoietic cell transplantation |
1 |
|
hematopoietic stem cell transplant |
1 |
|
hematopoietic stem cell transplantation (hsct) |
1 |
|
hemophagocytic lymphohistiocytosis |
1 |
|
hepatic veno-occlusive disease |
1 |
|
hepatoblastoma |
1 |
|
hla |
1 |
|
hsct |
1 |
|
human |
1 |
|
human in utero transplantation |
1 |
|
human leucocyte antigen |
1 |
|
human leucocyte antigen (hla) |
1 |
|
human leukocyte antigen |
1 |
|
human nk cell |
1 |
|
hypodiploid acute lymphoblastic leukemia |
1 |
|
immunity |
1 |
|
immunization |
1 |
|
immunogenetics |
1 |
|
immunologic reconstitution after transplantation |
1 |
|
immunology |
1 |
|
immunophenotyping |
1 |
|
immunosuppressive therapy |
1 |
|
incidence |
1 |
|
infant all |
1 |
|
infant aml |
1 |
|
infant leukemia |
1 |
|
infection |
1 |
|
iron overload |
1 |
|
keratinocyte growth factor |
1 |
|
killer cell immunoglobulin-like receptor |
1 |
|
killer cell immunoglobulin-like receptors (kir) |
1 |
|
killer cells |
1 |
|
killer-cell immunoglobulin-like receptor |
1 |
|
killer-cell immunoglobulin-like receptor (kir) |
1 |
|
kir match |
1 |
|
kir mismatch |
1 |
|
kir polymorphism |
1 |
|
kir-hla mismatch |
1 |
|
kir2dl1 allelotyping |
1 |
|
kirs genotyping |
1 |
|
large-volume leukapheresis |
1 |
|
late effects |
1 |
|
late sequelae |
1 |
|
lentivirus |
1 |
|
leukaemia |
1 |
|
leukoencephalopathy |
1 |
|
long-term follow-up |
1 |
|
long-term survival |
1 |
|
lymphoblastic leukemia |
1 |
|
lymphodepletion |
1 |
|
lymphoma |
1 |
|
lymphopoiesis |
1 |
|
lymphoproliferative disorder |
1 |
|
lymphphoid malignancies |
1 |
|
malnutrition |
1 |
|
manufacturing |
1 |
|
manufacturing of nk cell products |
1 |
|
matched sibling donor |
1 |
|
melanoma |
1 |
|
memory t cells |
1 |
|
mice-scid |
1 |
|
microfluidic |
1 |
|
minimal residual disease |
1 |
|
mismatched transplantation |
1 |
|
mortality |
1 |
|
mrc aml12 |
1 |
|
multiple thresholds |
1 |
|
myelodysplastic syndromes |
1 |
|
natural killer |
1 |
|
natural killer (nk) cell |
1 |
|
natural killer cell |
1 |
|
nk cell |
1 |
|
nk cell proliferation |
1 |
|
nk cells |
1 |
|
nk cells bmt |
1 |
|
nkg2d-nkg2dl interactions |
1 |
|
nod/scid chimeras |
1 |
|
non-hodgkin lymphoma |
1 |
|
non-myeloablative |
1 |
|
nutrition |
1 |
|
nutrition support |
1 |
|
nutritional support |
1 |
|
opportunistic infection |
1 |
|
ordered logistic model |
1 |
|
osteonecrosis |
1 |
|
osteosarcoma tumor initiating cells |
1 |
|
parainfluenza virus |
1 |
|
parenteral nutrition |
1 |
|
pediatric bmfs |
1 |
|
pediatric disorders |
1 |
|
pediatric leukemia |
1 |
|
pediatric oncology |
1 |
|
pediatric soild tumor |
1 |
|
pediatric solid tumors |
1 |
|
pediatric transplant |
1 |
|
pediatric transplantation |
1 |
|
peripheral blood stem cells |
1 |
|
pharmacokinetics |
1 |
|
plerixafor |
1 |
|
pneumocystis carinii |
1 |
|
pneumonia |
1 |
|
post-transplant complications |
1 |
|
post-transplantation cyclophosphamide |
1 |
|
prognostic factor |
1 |
|
prognostic factors |
1 |
|
pulmonary function |
1 |
|
pulmonary toxicity |
1 |
|
quality control |
1 |
|
qutologous |
1 |
|
rabbit antithymocyte globulin (ratg) |
1 |
|
radiosurgery |
1 |
|
rare variants |
1 |
|
reduced intensity conditioning regimen |
1 |
|
reduced-intensity regimen |
1 |
|
reduced-intensity transplantation |
1 |
|
refractory |
1 |
|
rejection |
1 |
|
relapsed |
1 |
|
respiratory |
1 |
|
respiratory virus |
1 |
|
ric |
1 |
|
risk factors |
1 |
|
safety |
1 |
|
sarcoma |
1 |
|
second transplant |
1 |
|
secondary acute myeloid leukemia |
1 |
|
set-valued system identification |
1 |
|
severe combined immune deficiency |
1 |
|
sickle cell disease |
1 |
|
single nucleotide polymorphism (snp) assay |
1 |
|
single-nucleotide polymorphism |
1 |
|
solid tumour |
1 |
|
statistics |
1 |
|
stem cell transplant |
1 |
|
stem cells |
1 |
|
stool |
1 |
|
survivor |
1 |
|
t cell |
1 |
|
t cell depleted |
1 |
|
t cells |
1 |
|
t-cell all |
1 |
|
t-cell depletion |
1 |
|
t-cell homeostatic proliferation |
1 |
|
t-cell receptor beta cdr3 size spectratyping |
1 |
|
t-cell receptor excision circle |
1 |
|
tel-aml1 |
1 |
|
thalasssaemia |
1 |
|
therapy-related |
1 |
|
thymoglobulin |
1 |
|
thymopoiesis |
1 |
|
thymus |
1 |
|
topotecan |
1 |
|
total body irradiation |
1 |
|
toxicity |
1 |
|
transduction |
1 |
|
transplant |
1 |
|
transplant tolerance |
1 |
|
treatment era |
1 |
|
treatment failure |
1 |
|
tumor therapy |
1 |
|
xenogeneic stem cell transplantation |
1 |
|
xlp |
1 |
